Q-omics provides the consensus-scored ELOA3P profile across patient tissues and cancer cell-line models. ELOA3P expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ELOA3P is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, ELOA3P RNA expression shows 5,231 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight HNSC, THCA, and COAD as cancer lineages where ELOA3P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELOA3P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELOA3P survival associations across molecular data types. ELOA3P RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELOA3P RNA expression–survival associations across cancer types. High ELOA3P expression shows unfavorable associations in HNSC, UCEC, TGCT, UVM, BLCA and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ELOA3P RNA expression.
This table summarizes ELOA3P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ELOA3P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELOA3P shows lower tumor expression in THCA. The THCA box plot shows higher ELOA3P RNA expression in normal versus tumor tissue (log2 FC = −0.004, t-test p = .023).
This table shows molecular features associated with ELOA3P in patient tissues and cancer cell lines. In patient samples, ELOA3P shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ELOA3P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BONE.
